Overview

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial for TPLWH (Trans People Living with HIV) who are stable on cART with an undetectable viral load or a detectable viral load but no resistance to NRTIs and InSTI. Following written consent and screening procedures, study subjects will undergo a switch (or will restart) of their combination antiretroviral therapy (cART) to Biktarvy. The goal of this research project is to recruit an understudied population into a controlled clinical trial aimed at optimizing TPLWH cART. This will be demonstrated by measuring viral load outcomes at regular intervals, with a focus on viral load results 48 weeks after Biktarvy initiation (primary outcome).
Phase:
Phase 4
Details
Lead Sponsor:
Chelsea and Westminster NHS Foundation Trust
Collaborators:
Gilead Sciences
Imperial College London
Treatments:
Emtricitabine